目的 研究2014—2016年5-氨基水杨酸类药物在武汉地区的应用情况和发展趋势，为临床合理用药提供参考。方法 采用世界卫生组织推荐的限定日剂量（DDD）为指标的分析方法，对武汉地区31家医院2014-2016年5-氨基水杨酸类药物的销售金额、用药频度（DDDs）、限定日费用（DDC）、排序比（B/A）等进行统计分析。结果 武汉地区2014—2016年5-氨基水杨酸类药物的销售总金额呈逐年上升趋势。美沙拉嗪的销售金额和DDDs均高居第1位，柳氮磺吡啶的销售金额和DDDs均以较大的差距位居第2位，巴柳氮和奥沙拉嗪的应用非常少。美沙拉嗪和柳氮磺吡啶的B/A均为1.00。结论 2014—2016年5-氨基水杨酸类药物的临床应用逐年增加，但是临床应用品种单一，主要以美沙拉嗪占据市场，且以缓释制剂应用最多，因此我国仍需加强对于治疗溃疡性结肠炎药物的研发。

Objective To analyze the application status of 5-aminosalicylic acids of 31 hospitals in Wuhan area from 2014 to 2016, and to provide references for rational clinical use of these drugs. Methods The total consumption sum, DDDs, and the sequenced ratio of 5-aminosalicylic acid applied in 31 hospitals in Wuhan area from 2014 to 2016 were analyzed statistically using the analytical method of the defined daily dose (DDD). Results Total consumption sum of 5-aminosalicylic acid in Wuhan area increased from 2014 to 2016. Consumption sum and DDDs of mesalazine ranked at the first place, followed by sulfasalazine with a significant gap, while Balsalazide and Olsalazine ranked at the bottom. B/A of mesalazine and sulfasalazine were both stabilized at 1.00. Conclusion The clinical utilization of 5-aminosalicylic acids increase year by year from 2014 to 2016, but the application varieties are single, and mesalazine has already occupied the market with sustained release preparation used mainly. Therefore, the research of drugs in treatment of ulcerative colitis need be strengthened in China.